Faculty

Back to Index
W. Martin Kast, PhD
Professor of Molecular Microbiology & Immunology, Obstetrics & Gynecology and Urology
Walter A. Richter Cancer Research Chair
Director Medical Biology Graduate Program
Molecular Microbiology and Immunology
NRT 7507 1450 Biggy Street Health Sciences Campus Los Angeles
+1 323 442 3870

Overview

W. Martin Kast, PhD is a Professor of Molecular Microbiology & Immunology, Obstetrics & Gynecology and Urology at the Norris Comprehensive Cancer Center (NCCC) of the University of Southern California in Los Angeles, CA. He holds the Walter A. Richter Cancer Research Chair and is the co-director of the NCCC Tumor Micro-environment program, the Director of the USC Medical Biology Graduate Program, a member of the USC Graduate School Admissions Committee, the Director of the Beckman Center for Immune Monitoring and the Assistant Dean of Academic Integrity. A native of the Netherlands, he earned his BS, MS, and PhD summa cum laude, from the University of Amsterdam in the Netherlands. He has and is serving on multiple Study Sections including the National Institute of Health and the Cancer Prevention and Research Institute of Texas. His research involves the design of therapeutic cancer vaccines directed against human papilloma virus (HPV) and prostate cancer. Several of his therapeutic HPV vaccines have or are currently been tried out in clinical trials. He studies how HPV enters cells and also studies the interaction of HPV with the human immune system to find out how HPV escapes immune detection and how to reverse that. He has published over 270 articles that have been quoted more than 21,000 times and lead to a publication h-index of 77. He is also the inventor on 18 patents. His research is supported by NIH and DOD grants. He is a recipient of the 1991 Antoni van Leeuwenhoek award, the 1991 Royal Netherlands Academy of Arts and Sciences award, the 2010 IRPC Eminent Scientist of the year Award for the USA, the 2012 Landsteiner Prize, the 2014 Mellon Award for graduate student mentoring, the 2015 STOP Cancer Award, the 2015 BeHEARD Award and the 2016 Affymetrix prize. He is an associate editor for the Journal of Translational Medicine, International Reviews of Immunology, HPV Today and Papillomavirus research. He also serves as the secretary/treasurer of the International Papillomavirus Society and on the advisory board of 4 biotechnology companies. In his free time he is a Scoutmaster and an actor.

Awards

Affymetrix: Affymetrix Prize, 2016

Rare Genomics Institute: BeHeard Ultimate Prize, 2015

STOP Cancer: STOP Cancer Award, 2015

University of Southern California: Mellon Award for Graduate Student Mentoring, 2014

University of Amsterdam: Landsteiner Prize, 2012

World Scientist Forum: North American Immunologist of the Year, 2010

IRPC: Eminent Scientist of the Year, 2010

Royal Netherlands Academy of Arts and Sciences: Royal Netherlands Academy of Arts & Sciences Award, 1991-1995

Netherlands Cancer Institute: Antoni van Leeuwenhoek Prize, 1991

Publications

A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression. Front Immunol. 2017; 8:563. View in: PubMed

The Cytoskeletal Adaptor Obscurin-Like 1 Interacts with the Human Papillomavirus 16 (HPV16) Capsid Protein L2 and Is Required for HPV16 Endocytosis. J Virol. 2016 Dec 01; 90(23):10629-10641. View in: PubMed

T cell ignorance is bliss: T cells are not tolerized by Langerhans cells presenting human papillomavirus antigens in the absence of costimulation. Papillomavirus Res. 2016 Dec; 2:21-30. View in: PubMed

Annexin A2 antibodies but not inhibitors of the annexin A2 heterotetramer impair productive HIV-1 infection of macrophages in vitro. Virol J. 2016 Nov 18; 13(1):187. View in: PubMed

Isoaspartylation appears to trigger small cell lung cancer-associated autoimmunity against neuronal protein ELAVL4. J Neuroimmunol. 2016 Oct 15; 299:70-78. View in: PubMed

Secretory Leukocyte Protease Inhibitor Expression and High-Risk HPV Infection in Anal Lesions of HIV-Positive Patients. J Acquir Immune Defic Syndr. 2016 Sep 1; 73(1):27-33. View in: PubMed

Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment. AIDS Patient Care STDS. 2016 Jul; 30(7):291-306. View in: PubMed

Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Hum Vaccin Immunother. 2016 Jun 2; 12(6):1418-29. View in: PubMed

Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells. J Interferon Cytokine Res. 2016 May; 36(5):291-301. View in: PubMed

Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C. Papillomavirus Res. 2015 Dec 1; 1:12-21. View in: PubMed

Herpes Simplex Virus downregulation of secretory leukocyte protease inhibitor enhances Human Papillomavirus type 16 infection. J Gen Virol. 2015 Nov 10. View in: PubMed

Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized poly-I:C. Clin Immunol. 2015 Sep 7. View in: PubMed

A novel murine model for evaluating bovine papillomavirus prophylactics/therapeutics for equine sarcoid-like tumours. J Gen Virol. 2015 Sep; 96(9):2764-8. View in: PubMed

Small molecule inhibitors of the annexin A2 heterotetramer prevent human papillomavirus type 16 infection. J Antimicrob Chemother. 2015 Jun; 70(6):1686-90. View in: PubMed

Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes. Prostate. 2015 Feb; 75(3):280-91. View in: PubMed

Molecular analysis of human papillomavirus virus-like particle activated langerhans cells in vitro. Methods Mol Biol. 2015; 1249:135-49. View in: PubMed

Functional Analysis of HPV-Like Particle-Activated Langerhans Cells In Vitro. Methods Mol Biol. 2015; 1249:333-50. View in: PubMed

Inhibition of langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression. J Immunol. 2014 May 15; 192(10):4748-57. View in: PubMed

Suppression of Langerhans cell activation is conserved amongst human papillomavirus a and ß genotypes, but not a µ genotype. Virology. 2014 Mar; 452-453:279-86. View in: PubMed

The evolving field of human papillomavirus receptor research: a review of binding and entry. J Virol. 2013 Jun; 87(11):6062-72. View in: PubMed

Human papillomavirus infection in head and neck cancer: the role of the secretory leukocyte protease inhibitor. Oncol Rep. 2013 May; 29(5):1962-8. View in: PubMed

Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability. Int Rev Immunol. 2012 Oct; 31(5):302-20. View in: PubMed

Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. J Pathol. 2012 Apr; 226(5):713-22. View in: PubMed

Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma. Int Rev Immunol. 2012 Feb; 31(1):22-42. View in: PubMed

Perspective for prophylaxis and treatment of cervical cancer: an immunological approach. Int Rev Immunol. 2012 Feb; 31(1):3-21. View in: PubMed

In this Issue: Targeting Human Papilloma Virus-Associated Disease, from Cervical to Head and Neck Carcinoma… and more. Int Rev Immunol. 2012 Feb; 31(1):1-2. View in: PubMed

A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies. J Transl Med. 2012; 10:218. View in: PubMed

The S100A10 Subunit of the Annexin A2 Heterotetramer Facilitates L2-Mediated Human Papillomavirus Infection. PLoS One. 2012; 7(8):e43519. View in: PubMed

Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. Prostate. 2012 Jan; 72(1):12-23. View in: PubMed

Notch-ing from T-cell to B-cell lymphoid malignancies. Cancer Lett. 2011 Sep 1; 308(1):1-13. View in: PubMed

Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy. J Immunother. 2011 Jul-Aug; 34(6):490-9. View in: PubMed

The level of secretory leukocyte protease inhibitor is decreased in metastatic head and neck squamous cell carcinoma. Int J Oncol. 2011 Jul; 39(1):185-91. View in: PubMed

Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer. Int Rev Immunol. 2011 Apr-Jun; 30(2-3):127-37. View in: PubMed

Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies. Int Rev Immunol. 2011 Apr-Jun; 30(2-3):71-86. View in: PubMed

Bovine papillomavirus DNA can be detected in keratinocytes of equine sarcoid tumors. Vet Microbiol. 2010 Dec 15; 146(3-4):269-75. View in: PubMed

Prevention is better than cure: the case for clinical trials of therapeutic cancer vaccines in the prophylactic setting. Mol Interv. 2010 Aug; 10(4):197-203. View in: PubMed

Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression. Cancer Res. 2010 May 15; 70(10):3955-64. View in: PubMed

Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer. 2010 Jan 15; 116(2):424-31. View in: PubMed

Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One. 2010; 5(5):e10471. View in: PubMed

Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages. Vaccine. 2009 Dec 30; 27 Suppl 6:G52-9. View in: PubMed

A major role for the minor capsid protein of human papillomavirus type 16 in immune escape. J Immunol. 2009 Nov 15; 183(10):6151-6. View in: PubMed

Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D. C. Head Neck. 2009 Nov; 31(11):1393-422. View in: PubMed

Immunogenicity of an HPV-16 L2 DNA vaccine. Vaccine. 2009 Oct 30; 27(46):6432-4. View in: PubMed

Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors. Clin Cancer Res. 2009 Oct 1; 15(19):6167-76. View in: PubMed

Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett. 2009 May 18; 277(2):126-32. View in: PubMed

Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition. Cancer Immunol Immunother. 2009 May; 58(5):719-28. View in: PubMed

Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer. Gynecol Oncol. 2009 May; 113(2):256-63. View in: PubMed

Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate. 2009 May 1; 69(6):571-84. View in: PubMed

Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J Immunol. 2009 Mar 1; 182(5):2919-28. View in: PubMed

Sperm protein 17 is expressed in the sperm fibrous sheath. J Transl Med. 2009; 7:61. View in: PubMed

Peptide-based vaccines for cancer: realizing their potential. Expert Rev Vaccines. 2008 Dec; 7(10):1533-45. View in: PubMed

rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer. Viral Immunol. 2008 Dec; 21(4):435-42. View in: PubMed

Notch-1 associates with IKKalpha and regulates IKK activity in cervical cancer cells. Oncogene. 2008 Oct 2; 27(44):5833-44. View in: PubMed

Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer. J Immunother. 2008 Oct; 31(8):693-703. View in: PubMed

Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells. Cancer Immunol Immunother. 2008 Jun; 57(6):789-97. View in: PubMed

A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev. 2008 Apr; 222:316-27. View in: PubMed

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother. 2008 Mar; 57(3):303-15. View in: PubMed

AKAP-4: a novel cancer testis antigen for multiple myeloma. Br J Haematol. 2008 Feb; 140(4):465-8. View in: PubMed

Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res. 2008 Feb 1; 68(3):861-9. View in: PubMed

Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer. 2008 Jan 15; 122(2):247-59. View in: PubMed

Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines. Cancer Immun. 2008; 8:8. View in: PubMed

Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV/GFP/IE1 loading of dendritic cells. J Transl Med. 2008; 6:56. View in: PubMed

Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol. 2007 Oct; 19(10):1223-34. View in: PubMed

A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol. 2007 Sep; 106(3):558-66. View in: PubMed

Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity. J Immunol. 2007 Jun 15; 178(12):7587-97. View in: PubMed

Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials. Int Rev Immunol. 2007 May-Aug; 26(3-4):197-222. View in: PubMed

The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors. Vaccine. 2007 Apr 30; 25(17):3437-44. View in: PubMed

Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res. 2007 Apr 15; 13(8):2385-91. View in: PubMed

A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17. J Immunol Methods. 2007 Apr 10; 321(1-2):86-93. View in: PubMed

Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets. 2007 Feb; 7(1):79-89. View in: PubMed

In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res. 2007 Feb 1; 67(3):1344-51. View in: PubMed

Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax encapsulated CTL/T helper peptides. J Transl Med. 2007; 5:26. View in: PubMed

Therapeutic vaccination for HPV induced cervical cancers. Dis Markers. 2007; 23(4):337-52. View in: PubMed

Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax. J Transl Med. 2007; 5:20. View in: PubMed

T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunol Immunother. 2006 Sep; 55(9):1142-50. View in: PubMed

Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine. 2006 Jun 12; 24(24):5235-44. View in: PubMed

Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. In Vitro Cell Dev Biol Anim. 2006 Mar-Apr; 42(3-4):89-95. View in: PubMed

Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant. J Transl Med. 2006; 4:42. View in: PubMed

Sperm protein 17 expression defines 2 subsets of primary esthesioneuroblastoma. Hum Pathol. 2005 Dec; 36(12):1289-93. View in: PubMed

Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro. Hum Immunol. 2005 Jul; 66(7):762-72. View in: PubMed

Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. J Immunol. 2005 Jun 1; 174(11):7172-8. View in: PubMed

Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells. Vaccine. 2005 Feb 25; 23(14):1720-9. View in: PubMed

Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res. 2005 Feb 15; 65(4):1570-6. View in: PubMed

The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management. Eur J Gynaecol Oncol. 2005; 26(2):129-42. View in: PubMed

Synopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy. J Transl Med. 2004 Jun 22; 2(1):20. View in: PubMed

Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes. Clin Cancer Res. 2004 May 15; 10(10):3301-8. View in: PubMed

Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors. Oncogene. 2004 May 13; 23(22):3972-9. View in: PubMed

Sperm protein 17 is expressed in human somatic ciliated epithelia. J Histochem Cytochem. 2004 Apr; 52(4):549-54. View in: PubMed

Peptide-based vaccines for cancer immunotherapy. Expert Opin Biol Ther. 2004 Feb; 4(2):181-98. View in: PubMed

Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine. 2004 Jan 2; 22(3-4):520-7. View in: PubMed

Cure of glioma: a space not yet occupied for the lesion. Cancer Invest. 2004; 22(3):479-80. View in: PubMed

Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes. Cancer Invest. 2004; 22(3):417-34. View in: PubMed

Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. Blood. 2004 Jan 1; 103(1):177-84. View in: PubMed

Synopsis of the 5th annual Cancer Vaccines and Immunotherapy Colloquium at Walker's Cay. Cancer Immunol Immunother. 2003 Oct; 52(10):655-60. View in: PubMed

Is sperm protein 17 a useful target for tumor immunotherapy? Blood. Is sperm protein 17 a useful target for tumor immunotherapy? Blood. 2003 Sep 15; 102(6):2308-9. View in: PubMed

Advances in prophylactic cancer vaccine research. Expert Rev Anticancer Ther. 2003 Aug; 3(4):537-45. View in: PubMed

Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine. 2003 Jul 4; 21(23):3219-27. View in: PubMed

Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res. 2003 Jul 1; 63(13):3478-82. View in: PubMed

Recent progress in tumour vaccine development. Expert Opin Investig Drugs. 2003 Jun; 12(6):971-81. View in: PubMed

CD4+ T cell matters in tumor immunity. Int Rev Immunol. 2003 Mar-Apr; 22(2):113-40. View in: PubMed

Cervical cancer vaccines: recent advances in HPV research. Viral Immunol. 2003; 16(2):111-21. View in: PubMed

Powered bySC CTSI